Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAUC: Vancomycin Dosing for Serious MRSA Infections
NCT04793152Recruiting
- Start
- Mar 2023
- Primary completion
- Jul 2029
- Modality
- Cyclic Peptides, Antimicrobial Peptides, Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of vancomycin in Staphylococcus aureus infection (2 arms). Primary endpoint: Treatment failure at 90 days. Started Mar 2023; status: recruiting.
02
Drugs
vancomycin
03
Conditions
Staphylococcus aureus infection
Beyond the preview
Go deeper on NCT04793152.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04793152.